A meeting is set to take place next month where US health officials will reassess a list of peptide drugs that have been a subject of controversy. The Food and Drug Administration has announced the participants of the meeting, which includes doctors and pharmacists. These individuals have financial connections to the industry surrounding these chemicals.

Further information about the meeting and the participants can be found through the FDA, as reported by KSAT 12. Details about the meeting's agenda and the specific peptide drugs being reconsidered are not provided here, but are available from the source.